Calypte(765254) scheint aufzuerstehen!
30.01.08 14:06
#151
Sylvia
News
Calypte Unveils Aware Messenger(TM), an Oral Specimen Collection Device Developed Especially for High-Throughput Testing Laboratories
PORTLAND, Ore.--(BUSINESS WIRE)--Jan. 30, 2008--Calypte Biomedical Corporation (OTCBB: CBMC), a developer, manufacturer and marketer of HIV diagnostic tests, today launched its latest new product, Aware Messenger(TM), an oral fluid sample collection device for collecting high-quality oral fluid specimens for high-throughput laboratory testing.
"We developed the Aware Messenger(TM) device in response to inquiries from several of our U.S. and international customers who requested a safe, simple and cost-effective alternative to currently marketed sampling devices. In addition, the device will meet the sample collection needs of potential customers who are seeking an alternative to blood testing but still prefer the advantages of high volume batch testing provided by traditional diagnostic methods such as EIA," stated Roger I. Gale, Calypte's President and CEO. "Aware Messenger(TM) is consistent with our growing product line which is aimed at improving the ease with which sample collection and testing can occur." Calypte Biomedical currently markets several diagnostic tests for HIV under the Aware(TM) brand outside the U.S. including its Aware(TM) HIV-1/2 OMT rapid oral fluid test.
According to Dr. Ronald W. Mink, Calypte's Chief Science Officer, "This product provides an exciting new opportunity for Calypte in the laboratory based diagnostics business. The Aware Messenger(TM) sample buffer is specifically formulated to promote sample stability and compatibility with the widest range of clinical laboratory tests. We believe that our tasteless swab, pre-designed for compatibility with conventional clinical assays, and providing a speedy collection without the need for additional processing at the laboratory, constitutes a significant competitive advantage in the oral specimen collector market. Further, we anticipate that users will find Aware Messenger(TM) to be ideally suited for the collection of oral fluid specimens containing antibodies and analytes of interest and will find that it provides excellent specimen stability, even at non-refrigerated temperatures. The design of the Aware Messenger(TM) product provides great potential for current and future expansion into diagnostic product opportunities in the U.S. and international markets."
The Aware Messenger(TM) oral fluid sample collection device uses an untreated, soft, tasteless swab and takes only 15-20 seconds to collect a sample rich in oral mucosal transudate. The device yields a large quantity of sample that is ready for testing without additional processing by the testing laboratory either immediately upon receipt or at a later time at a remote testing laboratory.
Collecting a sample with the Aware Messenger(TM) device involves a simple back and forth wipe of the upper and lower gum line with a swab, which is then placed into a buffer tube. The swab is expressed into the tube and discarded immediately after use. The tube containing the sample can then be delivered to the laboratory where the sample can be immediately and directly used in a suitably validated assay without processing, or stored for batch testing at a later time.
The current device is generic and will require validation by the user for each individual application for diagnostic use by the laboratory. A constantly growing body of literature supports the use of oral fluid specimens as an accurate alternative to blood for the testing for antibodies, antigens, drugs, and genetic testing. Aware Messenger(TM) will be available for shipment in February 2008 in boxes of 50 devices. Additional information about Aware Messenger(TM) can be found on Calypte's website (http://www.calypte.com).
About Calypte Biomedical:
Calypte Biomedical Corporation (www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the Aware(TM) HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2006 and its subsequent filings with the SEC.
CONTACT: Calypte Biomedical Corporation
Jerrold D. Dotson, 503-726-2227
VP-Finance
jdotson@calypte.com
or
Investor Relations:
CEOcast, Inc.
Dan Schustack, 212-732-4300
dschustack@ceocast.com
SOURCE: Calypte Biomedical Corporation
PORTLAND, Ore.--(BUSINESS WIRE)--Jan. 30, 2008--Calypte Biomedical Corporation (OTCBB: CBMC), a developer, manufacturer and marketer of HIV diagnostic tests, today launched its latest new product, Aware Messenger(TM), an oral fluid sample collection device for collecting high-quality oral fluid specimens for high-throughput laboratory testing.
"We developed the Aware Messenger(TM) device in response to inquiries from several of our U.S. and international customers who requested a safe, simple and cost-effective alternative to currently marketed sampling devices. In addition, the device will meet the sample collection needs of potential customers who are seeking an alternative to blood testing but still prefer the advantages of high volume batch testing provided by traditional diagnostic methods such as EIA," stated Roger I. Gale, Calypte's President and CEO. "Aware Messenger(TM) is consistent with our growing product line which is aimed at improving the ease with which sample collection and testing can occur." Calypte Biomedical currently markets several diagnostic tests for HIV under the Aware(TM) brand outside the U.S. including its Aware(TM) HIV-1/2 OMT rapid oral fluid test.
According to Dr. Ronald W. Mink, Calypte's Chief Science Officer, "This product provides an exciting new opportunity for Calypte in the laboratory based diagnostics business. The Aware Messenger(TM) sample buffer is specifically formulated to promote sample stability and compatibility with the widest range of clinical laboratory tests. We believe that our tasteless swab, pre-designed for compatibility with conventional clinical assays, and providing a speedy collection without the need for additional processing at the laboratory, constitutes a significant competitive advantage in the oral specimen collector market. Further, we anticipate that users will find Aware Messenger(TM) to be ideally suited for the collection of oral fluid specimens containing antibodies and analytes of interest and will find that it provides excellent specimen stability, even at non-refrigerated temperatures. The design of the Aware Messenger(TM) product provides great potential for current and future expansion into diagnostic product opportunities in the U.S. and international markets."
The Aware Messenger(TM) oral fluid sample collection device uses an untreated, soft, tasteless swab and takes only 15-20 seconds to collect a sample rich in oral mucosal transudate. The device yields a large quantity of sample that is ready for testing without additional processing by the testing laboratory either immediately upon receipt or at a later time at a remote testing laboratory.
Collecting a sample with the Aware Messenger(TM) device involves a simple back and forth wipe of the upper and lower gum line with a swab, which is then placed into a buffer tube. The swab is expressed into the tube and discarded immediately after use. The tube containing the sample can then be delivered to the laboratory where the sample can be immediately and directly used in a suitably validated assay without processing, or stored for batch testing at a later time.
The current device is generic and will require validation by the user for each individual application for diagnostic use by the laboratory. A constantly growing body of literature supports the use of oral fluid specimens as an accurate alternative to blood for the testing for antibodies, antigens, drugs, and genetic testing. Aware Messenger(TM) will be available for shipment in February 2008 in boxes of 50 devices. Additional information about Aware Messenger(TM) can be found on Calypte's website (http://www.calypte.com).
About Calypte Biomedical:
Calypte Biomedical Corporation (www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the Aware(TM) HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2006 and its subsequent filings with the SEC.
CONTACT: Calypte Biomedical Corporation
Jerrold D. Dotson, 503-726-2227
VP-Finance
jdotson@calypte.com
or
Investor Relations:
CEOcast, Inc.
Dan Schustack, 212-732-4300
dschustack@ceocast.com
SOURCE: Calypte Biomedical Corporation
14.02.08 19:38
#152
sertralin19
Es wird still um Calypte...
... das deucht mich fast, ein Kaufsignal zu sehen...
... das deucht mich fast, ein Kaufsignal zu sehen...
03.04.08 12:24
#154
calyritter_die_Ra.
junge, junge, junge...
was dich nicht alles deucht seralin....
mann, mann, mann, mann...du meinst wohl eher "täuscht"...muhahahahahahaa war aber abzusehen dieser verlauf. irgendwann wird der konsequente und permanente beschiß am shareholder eben entsprechend quittiert...
152. Es wird still um Calypte... sertralin19 14.02.08 19:38
... das deucht mich fast, ein Kaufsignal zu sehen...
mann, mann, mann, mann...du meinst wohl eher "täuscht"...muhahahahahahaa war aber abzusehen dieser verlauf. irgendwann wird der konsequente und permanente beschiß am shareholder eben entsprechend quittiert...
152. Es wird still um Calypte... sertralin19 14.02.08 19:38
... das deucht mich fast, ein Kaufsignal zu sehen...
17.04.08 14:17
#155
Sylvia
NEWS
Calypte's Aware(TM) HIV-1/2 OMT Approved as China's Only Rapid Oral HIV Test
Approval Enables Manufacturing, Marketing, Distribution and Sales
throughout China
Company to Hold Conference Call at 10:30 a.m. EDT Today to Discuss
Developments
PORTLAND, Ore.--(BUSINESS WIRE)--April 17, 2008--Calypte Biomedical Corporation (OTCBB:CBMC), a developer, manufacturer and marketer of HIV diagnostic tests, announced today that its Chinese subsidiary, Beijing Marr Bio-Pharmaceutical Co. Ltd. ("Beijing Marr"), has received registration and marketing approval for Calypte's Aware(TM) HIV-1/2 OMT (oral fluid) rapid test from the State Food and Drug Administration ("SFDA") of China. This approval makes the Aware(TM) HIV-1/2 OMT test the first and only SFDA approved rapid oral fluid HIV test in China.
Roger Gale, Calypte's Chairman and Chief Executive Officer, stated, "This is a major accomplishment for Calypte and we are thrilled to have received this long awaited approval which permits us to begin actively marketing our rapid diagnostic tests in China, one of the potentially largest HIV testing markets in the world. With the medical devices manufacturing permit received earlier this year, our Beijing Marr subsidiary is now able to manufacture, market, distribute and sell the Aware(TM) HIV-1/2 OMT test throughout the Peoples' Republic of China. China is committed to aggressively tackle the spread of its HIV epidemic and we believe that our Aware(TM) HIV-1/2 OMT (oral fluid) test can and will make a significant contribution to that effort. We appreciate the patience of those investors who have supported us through the long SFDA approval process, particularly our joint venture partners, the Marr Group." Mr. Gale added, "This approval also gives us, for the first time, a very valuable approval in the country of manufacture. Absence of this approval in the past has hampered our ability to register and market the test in a number of countries, a hurdle we can now overcome by producing the domestically approved Aware(TM) product in our Chinese factory. With this SFDA approval, we are now in a position to market and sell in countries representing a total population of nearly 3.7 billion, or over half of the worlds' population."
Dr. Ronald Mink, Chief Science Officer for Calypte, remarked, "This approval has validated our perseverance in pursuing the registration of a product in which we have long had confidence. The transformation of the SFDA over the past two to three years into a first tier agency matching the rigor and integrity of its U.S. and European counterparts resulted in a very thorough review of the Aware(TM) HIV-1/2 OMT (oral fluid) test. We believe that the Chinese authorities are now comfortable with this new technology, which expands the scope of testing platforms currently available in China. The SFDA's restructuring has resulted in a review process and timetable that is similar to what we see in the U.S. FDA. We believe these changes will benefit not only China, by setting a higher standard for new medical products, but will also benefit us, by setting a higher barrier to market entry for would-be competitors. Throughout the entire review process, we received continually positive feedback from the SFDA and we have been confident that our technology is solid and our registration would prevail."
David Harris, Beijing Marr's Chief Executive Officer, stated, "This is a very exciting moment for those of us at Beijing Marr who have worked very hard to gain this approval and ready the factory for manufacture, sale and distribution of the Aware(TM) HIV-1/2 OMT test. We have already received numerous inquiries from HIV program managers and scientists eager to use the product here in China. We now plan to ramp up our production capacity as we build our distribution network to fully realize the market potential of the Aware(TM) HIV-1/2 OMT test in China. Beijing Marr is committed to, and enthusiastic about, bringing this exciting new technology to the Chinese medical community."
Calypte operates in China through Beijing Marr, a joint venture between Calypte and the Marr Group established to manufacture Calypte's Aware(TM) line of rapid HIV tests, including the Aware(TM) HIV-1/2 OMT product for both the Chinese and international markets. Beijing Marr operates an ISO 13485:2003 certified manufacturing facility on the outskirts of Beijing. The Aware(TM) HIV-1/2 OMT product is a rapid test using oral fluid to diagnose HIV-1 or HIV-2 infection in as little as 20 minutes with an accuracy comparable to that of U.S. FDA approved blood based laboratory HIV EIA tests.
Conference Call:
Calypte will host a conference call today at 10:30 a.m. EDT. The call can be accessed in the U.S. by dialing 866-510-0707 and outside of the U.S. by dialing 617-597-5376. The participant pass code is 49798845. The conference call will also be webcast live at www.calypte.com. An audio replay of the call will be available through May 18, 2008, beginning approximately 1 hour after the conference call ends, by dialing 888-286-8010 in the U.S., or 617-801-6888 from outside of the U.S. The pass code for the playback is 64031187. The web cast will also be available for replay on Calypte's website.
About Calypte Biomedical:
Calypte Biomedical Corporation (http://www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the Aware(TM) HIV- 1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.
About The Marr Group:
The Marr Group is a private group of companies having a large and diverse number of investments and projects globally, principally in Europe, the Far East, the Middle East and the CIS.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2007 and its subsequent filings with the SEC.
CONTACT: Calypte Biomedical Corporation
Jerrold D. Dotson, 503-726-2227
VP-Finance
jdotson@calypte.com
or
CEOcast, Inc.
Investor Relations
Dan Schustack, 212-732-4300
dschustack@ceocast.com
SOURCE: Calypte Biomedical Corporation
Approval Enables Manufacturing, Marketing, Distribution and Sales
throughout China
Company to Hold Conference Call at 10:30 a.m. EDT Today to Discuss
Developments
PORTLAND, Ore.--(BUSINESS WIRE)--April 17, 2008--Calypte Biomedical Corporation (OTCBB:CBMC), a developer, manufacturer and marketer of HIV diagnostic tests, announced today that its Chinese subsidiary, Beijing Marr Bio-Pharmaceutical Co. Ltd. ("Beijing Marr"), has received registration and marketing approval for Calypte's Aware(TM) HIV-1/2 OMT (oral fluid) rapid test from the State Food and Drug Administration ("SFDA") of China. This approval makes the Aware(TM) HIV-1/2 OMT test the first and only SFDA approved rapid oral fluid HIV test in China.
Roger Gale, Calypte's Chairman and Chief Executive Officer, stated, "This is a major accomplishment for Calypte and we are thrilled to have received this long awaited approval which permits us to begin actively marketing our rapid diagnostic tests in China, one of the potentially largest HIV testing markets in the world. With the medical devices manufacturing permit received earlier this year, our Beijing Marr subsidiary is now able to manufacture, market, distribute and sell the Aware(TM) HIV-1/2 OMT test throughout the Peoples' Republic of China. China is committed to aggressively tackle the spread of its HIV epidemic and we believe that our Aware(TM) HIV-1/2 OMT (oral fluid) test can and will make a significant contribution to that effort. We appreciate the patience of those investors who have supported us through the long SFDA approval process, particularly our joint venture partners, the Marr Group." Mr. Gale added, "This approval also gives us, for the first time, a very valuable approval in the country of manufacture. Absence of this approval in the past has hampered our ability to register and market the test in a number of countries, a hurdle we can now overcome by producing the domestically approved Aware(TM) product in our Chinese factory. With this SFDA approval, we are now in a position to market and sell in countries representing a total population of nearly 3.7 billion, or over half of the worlds' population."
Dr. Ronald Mink, Chief Science Officer for Calypte, remarked, "This approval has validated our perseverance in pursuing the registration of a product in which we have long had confidence. The transformation of the SFDA over the past two to three years into a first tier agency matching the rigor and integrity of its U.S. and European counterparts resulted in a very thorough review of the Aware(TM) HIV-1/2 OMT (oral fluid) test. We believe that the Chinese authorities are now comfortable with this new technology, which expands the scope of testing platforms currently available in China. The SFDA's restructuring has resulted in a review process and timetable that is similar to what we see in the U.S. FDA. We believe these changes will benefit not only China, by setting a higher standard for new medical products, but will also benefit us, by setting a higher barrier to market entry for would-be competitors. Throughout the entire review process, we received continually positive feedback from the SFDA and we have been confident that our technology is solid and our registration would prevail."
David Harris, Beijing Marr's Chief Executive Officer, stated, "This is a very exciting moment for those of us at Beijing Marr who have worked very hard to gain this approval and ready the factory for manufacture, sale and distribution of the Aware(TM) HIV-1/2 OMT test. We have already received numerous inquiries from HIV program managers and scientists eager to use the product here in China. We now plan to ramp up our production capacity as we build our distribution network to fully realize the market potential of the Aware(TM) HIV-1/2 OMT test in China. Beijing Marr is committed to, and enthusiastic about, bringing this exciting new technology to the Chinese medical community."
Calypte operates in China through Beijing Marr, a joint venture between Calypte and the Marr Group established to manufacture Calypte's Aware(TM) line of rapid HIV tests, including the Aware(TM) HIV-1/2 OMT product for both the Chinese and international markets. Beijing Marr operates an ISO 13485:2003 certified manufacturing facility on the outskirts of Beijing. The Aware(TM) HIV-1/2 OMT product is a rapid test using oral fluid to diagnose HIV-1 or HIV-2 infection in as little as 20 minutes with an accuracy comparable to that of U.S. FDA approved blood based laboratory HIV EIA tests.
Conference Call:
Calypte will host a conference call today at 10:30 a.m. EDT. The call can be accessed in the U.S. by dialing 866-510-0707 and outside of the U.S. by dialing 617-597-5376. The participant pass code is 49798845. The conference call will also be webcast live at www.calypte.com. An audio replay of the call will be available through May 18, 2008, beginning approximately 1 hour after the conference call ends, by dialing 888-286-8010 in the U.S., or 617-801-6888 from outside of the U.S. The pass code for the playback is 64031187. The web cast will also be available for replay on Calypte's website.
About Calypte Biomedical:
Calypte Biomedical Corporation (http://www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the Aware(TM) HIV- 1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.
About The Marr Group:
The Marr Group is a private group of companies having a large and diverse number of investments and projects globally, principally in Europe, the Far East, the Middle East and the CIS.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2007 and its subsequent filings with the SEC.
CONTACT: Calypte Biomedical Corporation
Jerrold D. Dotson, 503-726-2227
VP-Finance
jdotson@calypte.com
or
CEOcast, Inc.
Investor Relations
Dan Schustack, 212-732-4300
dschustack@ceocast.com
SOURCE: Calypte Biomedical Corporation
17.04.08 14:24
#156
Pate100
was bringt das wenn man nix verkauft?
wurden in den anderen Ländern wo der Test zugelassen wurde schon mal
irgend etwas verkauft? Leider nicht oder? warum ist das so?
irgend etwas verkauft? Leider nicht oder? warum ist das so?
18.04.08 17:57
#158
calyritter_die_Ra.
Pate 100
du als einer meiner kritiker in der vergsangenheit: hast du es endlich eingesehen? das ist das, was ich euch schon seit jahren versuche zu erklären...
du siehst es jetzt am kurs. es wird abgeladen ohne ende...
du siehst es jetzt am kurs. es wird abgeladen ohne ende...
29.05.08 16:47
#159
kague
Calypte Biomedical Launches Calypte Life Sciences
Calypte Biomedical Launches Calypte Life Sciences Product Line
PORTLAND, Ore.--(BUSINESS WIRE)--May 29, 2008--Calypte Biomedical Corporation (OTCBB: CBMC), a developer, manufacturer and marketer of HIV diagnostic tests, today announced the launch of a new product line, Calypte Life Sciences. Calypte Life Sciences offers a broad range of recombinant proteins and antigens as well as proprietary reagents, buffers, and other specialty products to researchers and institutions seeking to develop and optimize immunodiagnostic assay systems. Calypte Life Sciences products are being distributed through a new on-line catalog (www.calyptelifesciences.com) as well as through Calypte's established worldwide network of distributors.
Roger I. Gale, Calypte's President and Chief Executive Officer, stated, "Calypte Life Sciences is a natural extension of what we already do and an important addition to our business, representing another potential revenue stream. Research & Development is one of the strengths of Calypte. We have, among our scientists, a tremendous reservoir of knowledge and experience and they are continuously coming up with novel approaches to solving some very difficult problems commonly encountered by assay developers. The Life Sciences catalog provides a further means by which we can capitalize on our R&D investment and bring new products to market quite quickly. Our Life Sciences division will serve the needs of a large and diverse group of customers that includes universities, governmental organizations, and private companies focusing primarily on assay development. It is particularly exciting that a significant portion of the market is based right here in the U.S."
Dr. Ronald Mink, Calypte's Chief Science Officer, stated that, "The products featured in our Life Sciences catalog are based mostly on technologies that we developed for our core diagnostics business. Many are truly unique. Our Gold Conjugate Clearant, which is currently featured on the home page of our on-line catalog, is one example of such a technology. It helps to reduce the amount of background color 'noise' on membrane-based rapid tests thereby improving their clinical performance. This is just one example and we have many more unique products that can help to improve the performance of diagnostic assays of all types. Through our Life Sciences catalog we are making these products broadly available to researchers and creating additional opportunities for developing better, faster and more cost effective diagnostic products."
Christopher P. Kafka, Vice President of Business Development, stated, "We have been testing the market to evaluate our products and to receive feedback on our new on-line catalog. I am happy to say that the response we have received leading up to our formal launch has been very positive. We have already seen our first sales and in the coming months we plan to aggressively promote our new Life Sciences offerings at major conferences such as the general meeting of the American Society for Microbiology (ASM) in early June, and the annual meeting of the American Association for Clinical Chemistry (AACC) in late July, as well as through online and print media."
About Calypte Biomedical:
Calypte Biomedical Corporation (www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the Aware(TM) HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by managements. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2007 and relate to our ability to obtain sufficient financing, if and as needed, and access funds from our existing financing arrangements, in order to continue our current and future operations, and whether demand for our test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. We assume no obligation to, and do not currently intend to, update these forward-looking statements.
CONTACT: Company:
Calypte Biomedical Corporation
Jerrold D. Dotson, VP-Finance
503-726-2227
jdotson@calypte.com
or
Investor Relations:
CEOcast, Inc.
Dan Schustack
212-732-4300
dschustack@ceocast.com
SOURCE: Calypte Biomedical Corporation
PORTLAND, Ore.--(BUSINESS WIRE)--May 29, 2008--Calypte Biomedical Corporation (OTCBB: CBMC), a developer, manufacturer and marketer of HIV diagnostic tests, today announced the launch of a new product line, Calypte Life Sciences. Calypte Life Sciences offers a broad range of recombinant proteins and antigens as well as proprietary reagents, buffers, and other specialty products to researchers and institutions seeking to develop and optimize immunodiagnostic assay systems. Calypte Life Sciences products are being distributed through a new on-line catalog (www.calyptelifesciences.com) as well as through Calypte's established worldwide network of distributors.
Roger I. Gale, Calypte's President and Chief Executive Officer, stated, "Calypte Life Sciences is a natural extension of what we already do and an important addition to our business, representing another potential revenue stream. Research & Development is one of the strengths of Calypte. We have, among our scientists, a tremendous reservoir of knowledge and experience and they are continuously coming up with novel approaches to solving some very difficult problems commonly encountered by assay developers. The Life Sciences catalog provides a further means by which we can capitalize on our R&D investment and bring new products to market quite quickly. Our Life Sciences division will serve the needs of a large and diverse group of customers that includes universities, governmental organizations, and private companies focusing primarily on assay development. It is particularly exciting that a significant portion of the market is based right here in the U.S."
Dr. Ronald Mink, Calypte's Chief Science Officer, stated that, "The products featured in our Life Sciences catalog are based mostly on technologies that we developed for our core diagnostics business. Many are truly unique. Our Gold Conjugate Clearant, which is currently featured on the home page of our on-line catalog, is one example of such a technology. It helps to reduce the amount of background color 'noise' on membrane-based rapid tests thereby improving their clinical performance. This is just one example and we have many more unique products that can help to improve the performance of diagnostic assays of all types. Through our Life Sciences catalog we are making these products broadly available to researchers and creating additional opportunities for developing better, faster and more cost effective diagnostic products."
Christopher P. Kafka, Vice President of Business Development, stated, "We have been testing the market to evaluate our products and to receive feedback on our new on-line catalog. I am happy to say that the response we have received leading up to our formal launch has been very positive. We have already seen our first sales and in the coming months we plan to aggressively promote our new Life Sciences offerings at major conferences such as the general meeting of the American Society for Microbiology (ASM) in early June, and the annual meeting of the American Association for Clinical Chemistry (AACC) in late July, as well as through online and print media."
About Calypte Biomedical:
Calypte Biomedical Corporation (www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the Aware(TM) HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by managements. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2007 and relate to our ability to obtain sufficient financing, if and as needed, and access funds from our existing financing arrangements, in order to continue our current and future operations, and whether demand for our test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. We assume no obligation to, and do not currently intend to, update these forward-looking statements.
CONTACT: Company:
Calypte Biomedical Corporation
Jerrold D. Dotson, VP-Finance
503-726-2227
jdotson@calypte.com
or
Investor Relations:
CEOcast, Inc.
Dan Schustack
212-732-4300
dschustack@ceocast.com
SOURCE: Calypte Biomedical Corporation
13.10.08 15:06
#160
kinu
news - können tote auferstehen???
13 Oktober 2008 02:00 PM Central Europe Summer Time
Calypte Biomedical Corporation Receives Large Order for Aware Diagnostic Test from Middle Eastern Distributor
New Sales Initiative Beginning to Yield Results
PORTLAND, Ore.--(BUSINESS WIRE)--Calypte Biomedical Corporation (OTCBB: CBMC), a developer, manufacturer and marketer of HIV diagnostic tests, announced today that it has received an order for 50,000 tests of its Aware™ HIV-1/2 OMT product from LifeLine Scientific, its newly appointed distributor for the UAE and several other countries in the region. The purchase is the first large order resulting from a newly implemented sales initiative.
Donald Taylor, Calypte’s President and Chief Executive Officer, stated, “I am delighted to announce that our local office in Dubai has signed such a significant order LifeLine Scientific is affiliated with a leading provider of healthcare in Abu Dhabi and has direct access to an expansive network of hospitals and pharmacies through which it plans to distribute Calypte’s oral fluid HIV tests.”
Mr. Taylor continued, “This order is the first result of our new sales initiative and reflects the hard work and commitment shown by our people around the world. It also shows the growing market acceptance of our Aware™ HIV-1/2 OMT product. While testing with oral fluid is clearly preferred by patients, easier to do, and safer than testing with blood, it has, nonetheless, faced significant adoption hurdles. As this UAE order demonstrates, we are on the right track and beginning to make headway. We are working hard in Africa, the Middle East, India and numerous other countries around the world to close more deals and build on the momentum we are gaining.”
Mr. Taylor concluded, “I have been on board for just over three months with a clear mission. This is the firststep in our primary objective to increase sales of our products worldwide. I am looking forward to many others in the months and years to come.”
Calypte will begin production as soon as the purchaser’s irrevocable letter of credit is approved.
About Calypte Biomedical Corporation:
Calypte Biomedical Corporation is a US-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the Aware™ HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases. For more information, visit www.calypte.com.
Calypte Biomedical Corporation Receives Large Order for Aware Diagnostic Test from Middle Eastern Distributor
New Sales Initiative Beginning to Yield Results
PORTLAND, Ore.--(BUSINESS WIRE)--Calypte Biomedical Corporation (OTCBB: CBMC), a developer, manufacturer and marketer of HIV diagnostic tests, announced today that it has received an order for 50,000 tests of its Aware™ HIV-1/2 OMT product from LifeLine Scientific, its newly appointed distributor for the UAE and several other countries in the region. The purchase is the first large order resulting from a newly implemented sales initiative.
Donald Taylor, Calypte’s President and Chief Executive Officer, stated, “I am delighted to announce that our local office in Dubai has signed such a significant order LifeLine Scientific is affiliated with a leading provider of healthcare in Abu Dhabi and has direct access to an expansive network of hospitals and pharmacies through which it plans to distribute Calypte’s oral fluid HIV tests.”
Mr. Taylor continued, “This order is the first result of our new sales initiative and reflects the hard work and commitment shown by our people around the world. It also shows the growing market acceptance of our Aware™ HIV-1/2 OMT product. While testing with oral fluid is clearly preferred by patients, easier to do, and safer than testing with blood, it has, nonetheless, faced significant adoption hurdles. As this UAE order demonstrates, we are on the right track and beginning to make headway. We are working hard in Africa, the Middle East, India and numerous other countries around the world to close more deals and build on the momentum we are gaining.”
Mr. Taylor concluded, “I have been on board for just over three months with a clear mission. This is the firststep in our primary objective to increase sales of our products worldwide. I am looking forward to many others in the months and years to come.”
Calypte will begin production as soon as the purchaser’s irrevocable letter of credit is approved.
About Calypte Biomedical Corporation:
Calypte Biomedical Corporation is a US-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the Aware™ HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases. For more information, visit www.calypte.com.
07.07.09 10:45
#161
calyritter_die_Ra.
na kino, watt macht caly?
erst amex, dann otc, jetzt nur noch pinkshit? aber ihr planlosen habt es ja immer besser gewußt als ich, gelle?
jetzt biste selber stumpf wie ne tischkante, wa?
selber schuld...
jetzt biste selber stumpf wie ne tischkante, wa?
selber schuld...
30.07.10 09:12
#162
buran
nächste Woche 20 USD !
eine Überraschung sthet an
der Vorstand ist so besoffen in den letzten Tagen gewesen
dass
die sich an der Börse haben eintragen lassen
und
mit sämtlichen Kapital
haben
die sich eintragen lassen
VH
voll da
die Sekretärin durchgevögelt
und
entlassen
der Laden ist komplett abgemeldet
und
lebt jetzt vom Geld der Aktiengeschäfte
20 USD !!!
in nur 3 Wochen !!!
MfG Buran
der Vorstand ist so besoffen in den letzten Tagen gewesen
dass
die sich an der Börse haben eintragen lassen
und
mit sämtlichen Kapital
haben
die sich eintragen lassen
VH
voll da
die Sekretärin durchgevögelt
und
entlassen
der Laden ist komplett abgemeldet
und
lebt jetzt vom Geld der Aktiengeschäfte
20 USD !!!
in nur 3 Wochen !!!
MfG Buran